The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 123 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] Ness-Abramof, 2002, Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese., Obes Res sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] Smith, 1996, Localization of 11β-hydroxysteroid dehydrogenase type II in human epithelial tissues., J Clin Endocrinol Metab source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] Pecori Giraldi, 2007, Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series., J Clin Endocrinol Metab source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] Elamin, 2008, Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses., J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] Batista, 2007, Diagnostic tests for children who are referred for the investigation of Cushing syndrome, Pediatrics source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 1,101–1,200 of 2,716
Park, S. Y., Oh, Y. T., Jung, D. C., & Rhee, Y. (2015) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000269 · Cited by 12
“Nevertheless, there is a limitation in predicting the adenoma with hypercortisolism by using the clinical features, such as increased BMD, because many of the patients with a cortisol-producing incidentaloma do not show overt clinical features of it.(6) In addition, patients without Cushing syndrome (ie, type 2 diabet…”
BackgroundMethodInfluentialHair cortisol concentration in a population without hypothalamic–pituitary–adrenal axis disorders
Cieszyński, Ł., Jendrzejewski, J., Wiśniewski, P., Owczarzak, A., & Sworczak, K. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/90038 · Cited by 14
Giorgi, R. B., Correa, M. V., Costa‐Barbosa, F. A., & Kater, C. E. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00385 · Cited by 14
Factitious Cushing's Syndrome: A Diagnosis to Consider When Evaluating Hypercortisolism
Pineyro, M. M., Redes, L., Mattos, S. D., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00129 · Cited by 12
Cushing's disease—from Minnie G to key issues in the early 21st century
Kelsall, A., & Newell-Price, J. D. C. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30343-2 · Cited by 13
Self-citationHuayllas, M. K. P., Sirineni, G. K. R., Smith, L. M., Gallagher, J. C., Singh, R., Netzel, B. C., & Kater, C. E. (2020) · American Journal of Roentgenology · doi:10.2214/ajr.19.21753 · Cited by 16
William F. Young (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00016-2 · Cited by 18
Identification of glucocorticoid-related molecular signature by whole blood methylome analysis
Armignacco, R., Jouinot, A., Bouys, L., Septier, A., Lartigue, T., Néou, M., Gaspar, C., Perlemoine, K., Braun, L., Riester, A., et al. (2022) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-214865 · Cited by 12
Vogg, N., Müller, T., Floren, A., Dandekar, T., Scherf‐Clavel, O., Faßnacht, M., Kroiß, M., & Kurlbaum, M. (2022) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2022.07.006 · Cited by 14
Reliability of the diagnostic tests for Cushing’s syndrome performed in a tertiary referral center
Güneş, M., Celik, O., & Kadıoğlu, P. (2012) · Pituitary · doi:10.1007/s11102-012-0387-7 · Cited by 12
Yang, Y., Sheng, M., Huang, F., Bu, D., Liu, X., Yao, Y., Dai, C., Sun, B., Zhu, J., Jiao, Y., et al. (2013) · Pituitary · doi:10.1007/s11102-013-0535-8 · Cited by 12
“Transsphenoidal surgery is the primary choice of Cushing disease treatment with reported remission rates of 69–93 % [25, 26].”
BackgroundFeo, Ó., Giraldo-Grueso, M., Puentes, J. C., & Harker, P. (2017) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0037-1604409 · Cited by 12
Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas
Karamouzis, I., Berardelli, R., Prencipe, N., Berton, A. M., Bona, C., Stura, G., Corsico, M., Gasco, V., Maccario, M., Ghigo, E., et al. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0361-0 · Cited by 12
“Patients were enrolled in this study based on the following criteria: (1) imaging features suggestive of pituitary adenoma [22]; (2) absence of any biochemical and clinical evidence of hormonal excess [exclusion of Cushing’s syndrome according to international criteria, including normal 24-h urinary free cortisol and/…”
MethodDisorders of the Endocrine System and of Metabolism
Schifter, M., McLean, M. P., & Sukumar, S. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch22 · Cited by 18
The Adrenal Cortex and Its Disorders
Hughes, C. R., Man, E., & Achermann, J. C. (2019) · Wiley eBooks · doi:10.1002/9781119152712.ch9 · Cited by 19
Geer, E. B., Ayala, A., Bonert, V., Carmichael, J. D., Gordon, M. B., Katznelson, L., Manuylova, E., Shafiq, I., Surampudi, V., Swerdloff, R. S., et al. (2017) · Pituitary · doi:10.1007/s11102-017-0801-2 · Cited by 11
Self-citationDepartment of Medicine, Q. E. H., Ng, C., Lam, T., Au Yeung, Y., Choi, C., Iu, Y., Shek, C., & Tiu, S. (2017) · Hong Kong Medical Journal · doi:10.12809/hkmj176240 · Cited by 11
The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas
Regazzo, D., Mondin, A., Scaroni, C. M., Occhi, G., & Barbot, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126469 · Cited by 13
“cortisol levels, tumoral corticotroph cells appear, at least partially, resistant to its negative feedback [7].”
BackgroundInfluentialCortisol: Analytical and clinical determinants
Vega‐Beyhart, A., Castro, M. A., Hanzu, F. A., & Casals, G. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.11.005 · Cited by 14
Giuliodori, A., Soudah, E., Malouf, J., Martel‐Duguech, L., Amodru, V., Gil, J., Hernández, J. A., Puig‐Domingo, M., Webb, S. M., & Valassi, E. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae004 · Cited by 13
Demir, A. N., Ayata, D., Öz, A., Sulu, C., Kara, Z., Şahin, S., Özaydın, D., Korkmazer, B., Arslan, S., Kızılkılıç, O., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae180 · Cited by 14
Venous thromboembolism in Cushing syndrome: results from an EuRRECa and Endo-ERN survey
Черенько, М. С., Appelman‐Dijkstra, N. M., Zurita, A. L. P., Biermasz, N. R., Dekkers, O. M., Klok, F. A., Reisch, N., Aulinas, A., Biagetti, B., Cannavò, S., et al. (2024) · Endocrine Connections · doi:10.1530/ec-24-0046 · Cited by 14
“Patients with suspected but not confirmed CS were excluded (according to the current guideline) (18).”
Medical management pathways for Cushing’s disease in pituitary tumors centers of excellence (PTCOEs)
Giustina, A., Uygur, M. M., Frara, S., Barkan, A. L., Biermasz, N. R., Chanson, P., Freda, P. U., Gadelha, M. R., Haberbosch, L., Kaiser, U. B., et al. (2025) · Pituitary · doi:10.1007/s11102-024-01485-x · Cited by 13
“More-over, centers were asked to report the number of medically treated patients in whom biochemical control was achieved according to current guidelines [20, 26].”
Lowering the dexamethasone suppression test cut-off: is it time yet?
Favero, V., Eller-Vainicher, C., Morelli, V., Scillitani, A., & Chiodini, I. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02679-1 · Cited by 12
Case report: nocardia infection associated with ectopic cushings
Rizwan, A., Sarfaraz, A., Jabbar, A., Akhter, J., & Islam, N. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-51 · Cited by 10
“Ectopic Cushings is a well recognized cause of Cushing’s syndrome, usually characterized by remarkably elevated levels of ACTH, elevated 24hour urine cortisol levels and severe/resistant hypokalemia, which can manifest as proximal myopathy [1,2].”
BackgroundAranda, G. B., López, C., Fernandez‐Ruiz, R., Esteban, Y., García-Eguren, G., Mora, M., Halperín, I., Casals, G., Enseñat, J., & Hanzu, F. A. (2017) · International Journal of Endocrinology · doi:10.1155/2017/2912763 · Cited by 11
Stachowska, B., Kuliczkowska-Płaksej, J., Kałużny, M., Grzegrzółka, J., Jończyk, M., & Bolanowski, M. (2020) · Endocrine · doi:10.1007/s12020-020-02468-1 · Cited by 15
Vega‐Beyhart, A., Laguna, J., Díaz-Catalán, D., Boswell, L., Mora, M., Halperín, I., Casals, G., & Hanzu, F. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.833644 · Cited by 14
Coexistence of bone and vascular disturbances in patients with endogenous glucocorticoid excess
Yano, C., Yokomoto‐Umakoshi, M., Fujita, M., Umakoshi, H., Yano, S., Iwahashi, N., Katsuhara, S., Kaneko, H., Ogata, M., Fukumoto, T., et al. (2022) · Bone Reports · doi:10.1016/j.bonr.2022.101610 · Cited by 12
“CS was diagnosed based on clinical findings in the Clinical Practice Guidelines of the Endocrine Society (Nieman et al., 2008).”
MethodPostoperative serum cortisol and Cushing disease recurrence in patients with corticotroph adenomas
Catalino, M. P., Moore, D. T., Ironside, N., Munoz, A. R., Coley, J., Jonas, R., Kearns, K., Min, L., Vance, M. L., Jane, J. A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad347 · Cited by 11
de Almeida, T. S., Rodrigues, T. D. C., Costenaro, F., Scaffaro, L. A., Farenzena, M., Gastaldo, F., & Czepielewski, M. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1224001 · Cited by 13
“In this step, non-invasive tests are initially recommended, such as the CRH test (CRH-t), the 8 mg dexamethasone suppression test (DST-8 mg), and a pituitary magnetic resonance imaging (MRI) (5, 8).”
BackgroundInfluentialLi, Y., Li, C., Qi, X., Yu, L. D., & Lin, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1177125 · Cited by 18
LC-MS/MS improves screening towards 21-hydroxylase deficiency
Ambroziak, U., Kępczyńska‐Nyk, A., Kuryłowicz, A., Wysłouch‐Cieszyńska, A., Małunowicz, E., Bartoszewicz, Z., Kondracka, A., Jaźwiec, R., Pawłowska, E., Szcześniak, M., et al. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.994599 · Cited by 11
“Cushing’s syndrome was diagnosed according to Endocrine Society guidelines [13].”
Cipoli, D. E., Martínez, E. Z., de Castro, M., & Moreira, A. C. (2012) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302012000900006 · Cited by 12
“Tests currently used to screen for CS are measurement of free cortisol in 24-hour urine (UFC), assessment of cortisol circadian rhythm using late-night serum and salivary cortisol levels (LNSF), and cortisol suppressibility by low doses of dexamethasone (1 mg-DST) (4).”
MethodMoreno, C. N., Delestienne, A., Marbaix, É., Aydın, S., Hörtnagel, K., Lechner, S., Sznajer, Y., Beauloye, V., Maiter, D. M., & Lysy, P. A. (2018) · Hormone Research in Paediatrics · doi:10.1159/000488761 · Cited by 11
Surgical Outcomes and Comorbidities in Cushing Disease: 30 Years of Experience in a Referral Center
Martínez-Ortega, A. J., Venegas-Moreno, E. M., Dios, E., Remón-Ruiz, P., Márquez-Rivas, J., Ruiz‐Valdepeñas, E. C., Kaen, A. M., Cano, D. A., & Soto‐Moreno, A. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.10.067 · Cited by 11
Adrenal incidentaloma: differential diagnosis and management strategies
Morelli, V., & Palmieri, S. (2018) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02868-7 · Cited by 14
Li, S., Sun, H., Ma, L., Zhu, Y., Xie, W., Sun, J., Zhao, L., Qing, B., Ren, Y., Tian, H., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002271 · Cited by 12
“In addition, all patients were screened for midnight serum cortisol in the Endocrinology and Metabolism Department before AVS, or a 1 mg dexamethasone overnight suppression test was performed with a midnight serum cortisol more than 50 nmol/l [13].”
MethodCaffarini, M., Armeni, T., Pellegrino, P., Cianfruglia, L., Martino, M., Offidani, A., Benedetto, G. D., Arnaldi, G., Campanati, A., & Orciani, M. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00227 · Cited by 13
Turan, H., Çatlı, G., Kardelen, A. D., Böber, E., Akıncı, A., Çetinkaya, S. Ç., Demirbaş, Ö., Er, E., Evliyaoğlu, S. O., Dündar, B. N., et al. (2021) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2021.2021.0152 · Cited by 13
How to Explore an Endocrine Cause of Hypertension
de Fréminville, J.-B., & Amar, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020420 · Cited by 11
“The origin is the adrenal glands in 20% of cases, the pituitary gland in 70% of cases, and paraneoplasic in 10% of cases [47].”
BackgroundAphidicolin inhibits cell proliferation via the p53-GADD45β pathway in AtT-20 cells
Kageyama, K., Sugiyama, A., Murasawa, S., et al. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0084 · Cited by 11
“Cushing’s disease is primarily caused by a pituitary adrenocorticotropic hormone (ACTH)-secreting tumor [1, 2].”
BackgroundAdrenocorticotropic Hormone-Independent Cushing Syndrome with Bilateral Cortisol-Secreting Adenomas
Ku, E. J., Hong, A. R., Kim, Y. A., et al. (2013) · Endocrinology and Metabolism · doi:10.3803/enm.2013.28.2.133 · Cited by 11
Habinshuti, J., Capiod, P., Nguyen, T. H., Justo, Y., Avila, F. J., Asensio, M. C., Bournel, F., Gallet, J., Vobornik, I., Fujii, J., et al. (2013) · Physical Review B · doi:10.1103/physrevb.87.184102 · Cited by 10
Evaluation of quantitative parameters for distinguishing pheochromocytoma from other adrenal tumors
Ohno, Y., Sone, M., Taura, D., Yamasaki, T., Kojima, K., Honda-Kohmo, K., Fukuda, Y., Matsuo, K., Fujii, T., Yasoda, A., et al. (2018) · Hypertension Research · doi:10.1038/s41440-017-0002-4 · Cited by 13
TSH ratio as a novel diagnostic method for Cushing’s syndrome
Tamada, D., Kitamura, T., Takahara, M., Tanaka, T., Takeda, M., Otsuki, M., & Shimomura, I. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej18-0101 · Cited by 10
Tsentidis, C., Bampilis, A., Ntova, V., Fragkos, D., Panos, C., Limniati, C., & Kassi, G. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0754-6464 · Cited by 10
Han, M., Cao, X., Zhao, C., Yang, L., Yin, N., Shen, P., Zhang, J., Gao, F., Ren, Y., Liang, D., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.544752 · Cited by 10
Kittithaworn, A., Dogra, P., Saini, J., Gruppen, E. G., Atkinson, E. J., Achenbach, S. J., Yu, K., Thangamuthu, K., Connelly, M. A., Dullaart, R. P. F., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae204 · Cited by 11
Findlay, M. C., Tenhoeve, S., Alt, J. A., Rennert, R. C., Couldwell, W. T., Evans, J., Collopy, S., Kim, W. B., Delery, W., Pacione, D. R., et al. (2024) · Neurosurgery · doi:10.1227/neu.0000000000003042 · Cited by 13
“36,37 Improved preoperative imaging evaluation of cavernous sinus invasion and advanced techniques for its intraoperative observation and treatment are critical to improve outcomes.”
Cardiovascular status in endogenous cortisol excess: the prospective CV-CORT-EX study
Morbach, C., Detomas, M., Sahiti, F., Hoffmann, K., Kroiß, M., Gelbrich, G., Frantz, S., Hahner, S., Heuschmann, P. U., Faßnacht, M., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae145 · Cited by 11
Morelli, V., Favero, V., Frigerio, S., Aresta, C., Pugliese, F., Salcuni, A. S., Risio, A., Eller-Vainicher, C., Palmieri, S., Cairoli, E., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf227 · Cited by 16
Rotolo, L., Galante, G., Coscia, K., Bissi, V., Tucci, L., Mezzullo, M., Gambineri, A., Vicennati, V., Zavatta, G., Pagotto, U., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf141 · Cited by 12
Therapeutic strategies for Cushing’s syndrome: an update
Ceccato, F., Barbot, M., Zilio, M., Albiger, N. M. E., Mantero, F., & Scaroni, C. M. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.991714 · Cited by 12
“In healthy people, the circadian cortisol rhythm is essential to wellbeing, and it is one of the fundamental aspects to consider in the diagnosis of CS [1,61].”
BackgroundMethodInfluentialEfficacy and Safety of Stereotactic Radiotherapy in Cushing’s Disease: A Single Center Experience
Apaydın, T., Özkaya, H. M., Durmaz, S. M., Meral, R., & Kadıoğlu, P. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1217-7365 · Cited by 10
“Cushing’s syndrome (CS) is associated with increased morbidity and mortality due to metabolic, cardiovascular, and skeletal system effects of hypercortisolemia [1, 2].”
BackgroundMethodTeuber, J. P., Nanba, K., Turcu, A. F., Chen, X., Zhao, L., Else, T., Auchus, R. J., Rainey, W. E., & Rege, J. (2021) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2021.105924 · Cited by 10
Tatsi, C., Bompou, M. E., Flippo, C. L., Keil, M. F., Chittiboina, P., & Stratakis, C. A. (2021) · Clinical Endocrinology · doi:10.1111/cen.14560 · Cited by 10
“CS diagnosis was based on criteria defined by the Endocrine Society guidelines and adjusted for the paediatric and adolescent population as previously described (abnormal measurements in at least two of the following criteria: Elevated 24 h urinary free cortisol [UFC], elevated midnight serum cortisol [>121 nmol/L in…”
Vincenzo, M. D., Martino, M., Lariccia, V., Giancola, G., Licini, C., Benedetto, G. D., Arnaldi, G., & Orciani, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816229 · Cited by 10
Costs and Its Determinants in Pituitary Tumour Surgery
Dekkers, A. J., de Vries, F., Najafabadi, A. H. Z., van der Hoeven, E. M., Verstegen, M. J. T., Pereira, A. M., van Furth, W. R., & Biermasz, N. R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.905019 · Cited by 14
“There are disease-speci fi c treatment guidelines (2, 3, 5 – 7), however, in clinical practice the evidence base of optimal management choices is rather limited.”
Cruz, K. J. C., de Oliveira, A. R. S., Fontenelle, L. C., Morais, J. B. S., Melo, S. R. D. S., dos Santos, L. R., de Sousa, T. G. V., de Freitas, S. T., Henriques, G. S., Bordin, S. A., et al. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03938-z · Cited by 14
“The reference standard for cortisol levels in the morning biological sample collection was set between 6.23 and 18.01 µg/dl [37].”
InfluentialNeurologic Complications of Nondiabetic Endocrine Disorders
Ishii, M. (2014) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000450966.68828.45 · Cited by 14
“Neuropsychiatric impairments from glucocorticoid excess include depression with fatigue and insomnia, but mania and anxiety may also be seen.(54,56) While improvement in the cognitive and neuropsychiatric impairments can be seen after treatment and cure of the underlying cause of glucocorticoid excess, these impairmen…”
BackgroundMethodUnmasking sarcoidosis following surgery for Cushing disease
Diernæs, J. E. F., Bygum, A., & Poulsen, P. L. (2014) · Dermato-Endocrinology · doi:10.4161/derm.29855 · Cited by 9
“A review of the literature (MeSH-terms “Cushing syndrome” AND “Sarcoidosis”; limits: humans, all languages, 1970–2014) revealed only five similar case reports.(1,2,5-9) Only one of these describes a similar case of EN as the presenting sign of underlying sarcoidosis.”
BackgroundTrementino, L., Ceccoli, L., Concettoni, C., Marcelli, G., Michetti, G., Boscaro, M., & Arnaldi, G. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0126-1 · Cited by 11
Dedov, I. I., Mel'nichenko, G. A., Dzeranova, L. K., Pigarova, E. A., Rozhinskaya, L. Y., Kadashev, B. A., Grigor’ev, A. Y., Astaf’eva, L. I., Shishkina, L. V., Vorontsov, A. V., et al. (2015) · Problems of Endocrinology · doi:10.14341/probl201561357-68 · Cited by 11
Etanercept-Induced Hypoglycemia And Improved Glycemic Control In A Patient With type 2 Diabetes
Farrokhi, F., Taylor, H. C., McBride, N. M., Milanesi, A., Ho, A. Y. Y., Ewing, A., Yu, R., Varadhan, L., Laing, R., Cheruvu, C. V. N., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.2.306 · Cited by 10
Die Klug-entscheiden-Initiative der Deutschen Gesellschaft für Innere Medizin
Feldkamp, J., Schott, M., Gogol, M., Quinkler, M. O., Blüher, M., Diederich, S., & Reincke, M. (2016) · Der Internist · doi:10.1007/s00108-016-0072-4 · Cited by 13
Manejo de los corticoides en la práctica clínica
Galofré, J. C. (2017) · Revista de medicina de la Universidad de Navarra · doi:10.15581/021.9148 · Cited by 10
Comparison of 1 mg versus 2 mg Dexamethasone Suppression Test in Patients with Obesity
Urwyler, S. A., Cupa, N., & Christ‐Crain, M. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-119128 · Cited by 11
“8 μg/dl) was used to determine normal cortisol suppression and exclude CS [13].”
MethodLechner, B., Heinrich, D. A., Nölting, S., Osswald-Kopp, A., Rubinstein, G., Sauerbeck, J., Beuschlein, F., & Reincke, M. (2018) · Der Internist · doi:10.1007/s00108-018-0505-3 · Cited by 10
Tuncer, F. N., Doğanşen, S. Ç., Serbest, E., Tanrıkulu, S., Ekici, Y., Bılgıç, B., & Yarman, S. (2018) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2018.0133 · Cited by 11
“The results were interpreted in accordance with current recommendations and guidelines (Casanueva et al. , 2006; Nieman et al. , 2008; Katznelson et al. , 2011, 2014; Melmed et al. , 2011).”
Zavatta, G., Dalmazi, G. D., Pizzi, C., Bracchetti, G., Mosconi, C., Balacchi, C., Pagotto, U., & Vicennati, V. (2018) · Endocrine · doi:10.1007/s12020-018-1801-3 · Cited by 10
Pasternak-Pietrzak, K., Moszczyńska, E., Jurkiewicz, E., & Szalecki, M. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2019.0040 · Cited by 12
“specificity 80% [42]) commits to further diagnostics in the direction of CS [43].”
BackgroundAssessment of 1 mg Dexamethasone Suppression Test in Patients with Obesity Before Bariatric Surgery
Yavuz, D. G., Apaydın, T., Günhan, H. G., & Uygur, M. M. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04865-x · Cited by 14
Dried urine and salivary profiling for complete assessment of cortisol and cortisol metabolites
Newman, M. S., Curran, D. A., & Mayfield, B. P. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100243 · Cited by 13
“Perhaps one of the most validated applications is the late-night salivary cortisol test used in the diagnosis of Cushing disease [10,40].”
BackgroundMethodDynamic Tests in Pituitary Endocrinology: Pitfalls in Interpretation during Aging
Caputo, M., Mele, C., Ferrero, A., Leone, I., Daffara, T., Marzullo, P., Prodam, F., & Aimaretti, G. (2021) · Neuroendocrinology · doi:10.1159/000514434 · Cited by 12
Kamilaris, C. D. C., Faucz, F. R., Andriessen, V. C., Nilubol, N., Lee, C. R., Ahlman, M. A., Hannah‐Shmouni, F., & Stratakis, C. A. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab007 · Cited by 10
“Plasma ACTH was undetectable (<5 pg/mL [5-46]) suggesting ACTH-independent CS and dehydroepiandrosterone sulfate (DHEAS) was <0.”
BackgroundMethodCushing’s Syndrome With Nocardiosis: A Case Report and a Systematic Review of the Literature
Zhang, D., Jiang, Y., Lü, L., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.640998 · Cited by 10
“CS was diagnosed according to the clinical practice guideline of the diagnosis of CS (9).”
MethodChen, K., Chen, S., Lü, L., Zhu, H., Zhang, X., Tong, A., Pan, H., Wang, R., & Lu, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.720823 · Cited by 11
Zavatta, G., Dalmazi, G. D., Altieri, P., Pelusi, C., Golfieri, R., Mosconi, C., Balacchi, C., Borghi, C., Cosentino, E. R., Cintio, I. D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.09.002 · Cited by 11
Approach to the Patient with an Incidental Adrenal Mass
He, X., Peter, P. R., & Auchus, R. J. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.009 · Cited by 13
Draft of the clinical practice guidelines “Adrenal incidentaloma”
Beltsevich, D. G., Troshina, E. A., Mel'nichenko, G. A., Platonova, N. M., Ladygina, D. O., & Chevais, A. (2021) · Endocrine Surgery · doi:10.14341/serg12712 · Cited by 12
Chen, Z., Jia, Q., Zhao, Z., Zhang, Q., Chen, Y., Qiao, N., Ye, Z., Ji, C., Zhang, Y., He, W., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac280 · Cited by 12
Lack of sensitivity of diagnostic Cushing-scores in Germany: a multicenter validation
Braun, L., Vogel, F., Rubinstein, G., Zopp, S., Nowak, E., Constantinescu, G. A., Masjkur, J. R., Detomas, M., Pamporaki, C., Altieri, B., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac016 · Cited by 11
Marko, N. F., Hamrahian, A. H., Hatipoğlu, B., & Weil, R. J. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.05.039 · Cited by 10
“Most cycles of excess are associated with both biochemical excess and clinical signs of CS (72% of patients), although only one or the other may occur individually (15% and 13%, respectively ).(3,10)”
BackgroundMethodCurrent views of the screening and diagnostics of endogenous hypercorticism
Белая, Ж. Е., Рожинская, Л. Я., Mel'nichenko, G. A., & Dedov, I. I. (2012) · Problems of Endocrinology · doi:10.14341/probl201258435-41 · Cited by 14
“Для повышения чувствительности теста точка разделения была снижена до 50 нмоль/л (уровень кортизола в крови после дексаметазона) [17], что позволяет добиться высокой чувствительности (более 95%) и приемлемой специфичности (80%) [26].”
InfluentialMatching the Diameter of ePTFE Bypass Prosthesis with a Native Artery Improves Neoendothelialization
Çıkırıkçıoğlu, M., Pektok, E., Cikirikcioglu, Y. B., Lujan, S. M. O., Tille, J., Kalangos, A., & Walpoth, B. H. (2008) · European Surgical Research · doi:10.1159/000118029 · Cited by 10
Using an algorithmic approach to secondary amenorrhea: Avoiding diagnostic error
Roberts‐Wilson, T. K., Spencer, J. B., & Fantz, C. R. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.04.007 · Cited by 11
Telomeres, aging and Cushing's syndrome: Are they related?
Aulinas, A., Vives, A. S., Valassi, E., Mato, E., Crespo, I., Resmini, E., Roig, O., Bell, O. L., & Webb, S. M. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.10.006 · Cited by 11
Repetto, E. M., González, D., Jacobsen, D., Smithuis, F., Jamardo, J., Cano, M., Aranda, C., Oneto, A., Berg, G. A., & Fabre, B. R. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0585 · Cited by 12
“In fact, determination of late-night salivary cortisol concentration is recommended for the screening of patients with suspected Cushing’s syndrome (CS) [2].”
BackgroundMethodInfluentialGuarnotta, V., Pizzolanti, G., Ciresi, A., & Giordano, C. S. D. S. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0839-7 · Cited by 11
“The diagnosis of CD was based on clinical features and laboratory assessments according to the clinical practice guidelines and a consensus statement [22, 23].”
MethodPetramala, L., D’Elia, L., Iannucci, G., Concistrè, A., Zinnamosca, L., Marinelli, C., VINCENTIS, G. D., Ciardi, A., Toma, G. D., & Letizia, C. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.4.488 · Cited by 12
Disorders of the adrenal cortex
Sherlock, M., & Gurnell, M. (2020) · doi:10.1093/med/9780198746690.003.0249 · Cited by 10
Tan, S. Y. T., Tan, H. C., Zhu, L., Loh, L. M., Lim, D. S. T., Swee, D. S., Chan, Y. L., Lim, H. B., Ling, S. L., Ou, E. J., et al. (2023) · Endocrine Connections · doi:10.1530/ec-23-0004 · Cited by 10
“It is already in use as one of the diagnostic tests for Cushing’s syndrome (15).”
Dogra, P., Šambula, L., Saini, J., Drake, M. T., Athimulam, S., Tsagarakis, S., Vassiliadi, D. A., Antonopoulou, V., Nathani, R., Zhang, C. D., et al. (2025) · Clinical Endocrinology · doi:10.1111/cen.70048 · Cited by 9
“Patients with CS were diagnosed per established clinical practice guidelines [12].”
Inoue, K., Horikoshi, H., Omura, M., Tsurutani, Y., Saito, J., & Nishikawa, T. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac167 · Cited by 9
“Endothelin-1[1-31]: a novel autocrine-paracrine regulator of human adrenal cortex 12 secretion and growth.”
BackgroundMoustaki, M., Markousis‐Mavrogenis, G., Vryonidou, A., Paschou, S. Α., & Mavrogeni, S. I. (2023) · Endocrine · doi:10.1007/s12020-023-03623-0 · Cited by 11
“…tissue in the extremities and lipogenesis prevailing in truncal sub-cutaneous and visceral adipose tissue, as well as in facial adipose tissue, giving rise to the classic phenotype of central adiposity in CS, accompanied by supraclavicular fat pads, buffalo hump and moon facies [1, 4, 7, 8].”
Long-Term Glucocorticoid Exposure and Incident Cardiovascular Diseases—The Lifelines Cohort
van der Valk, E. S., Mohseni, M., Iyer, A. M., den Hurk, M. J. B. V., Lengton, R., Kuckuck, S., Wester, V. L., Leenen, P. J. M., Dik, W. A., Visser, J. A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae081 · Cited by 10
Valizadeh, M., Abiri, B., Hosseinpanah, F., & Grossman, A. B. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13789 · Cited by 11
“Patients with non-neoplastic hypercortisolism states are unlikely to have UFC elevations exceeding four times the upper limit of normal [154].”
BackgroundDeFronzo, R. A., Auchus, R. J., Bancos, I., Blonde, L., Busch, R. S., Buse, J. B., Findling, J. W., Fonseca, V. A., Frías, J. P., Hamidi, O., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-081121 · Cited by 12
Self-citationNT-proBNP levels in patients with primary hyperaldosteronism and autonomous cortisol cosecretion
Hirsch, A., Adolf, C., Stüfchen, I., Beuschlein, F., Brüdgam, D., Bidlingmaier, M., Reincke, M., & Quinkler, M. O. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae119 · Cited by 9
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.